fbpx Skip to main content

People with psoriasis have double the odds of celiac disease versus people without psoriasis

Individuals with psoriasis have double the odds of having celiac disease (CD) versus individuals without psoriasis, according to a research letter published online Feb. 9 in the Journal of the American Academy of Dermatology.

Marina Z. Joel, from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the association between psoriasis and CD using data from 316,166 adults participating in the All of Us Research Program.

The researchers found that of the 6,476 patients with psoriasis, 1.65 percent had CD versus 0.49 percent of the 309,690 patients without psoriasis. There were significant differences in age (mean, 61.4 versus 54.0 years), race (69.1 versus 47.8 percent White), body mass index (BMI; mean, 31.0 versus 29.8 kg/m²), smoking (46.0 versus 39.4 percent), and autoimmune disease (22.6 versus 6.4 percent) for participants with psoriasis versus those without psoriasis. After adjusting for age, sex, race/ethnicity, smoking status, autoimmune diseases linked to psoriasis and CD (systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes mellitus, autoimmune thyroiditis, vitiligo, and alopecia areata), and BMI in the model, psoriasis remained significantly associated with CD (odds ratio, 2.05).

“While the pathophysiologic mechanism behind the association between psoriasis and CD is unclear, several explanations have been proposed. Genome-wide association studies have found that many susceptibility loci for psoriasis overlap with those for CD. Because both psoriasis and CD are T-cell driven disorders, there could be shared immunogenic mechanisms between the two,” the authors write. “Further studies are required to better understand the pathophysiologic mechanisms linking psoriasis and CD.”

One author disclosed financial ties to Advarra.

You May Also Like::  Drug Makers Raise Prices on 500 Prescription Drugs

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More